Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
What happened?
Headed to $9 imo
Wow what's happening-GREEN?
Novocure Converts More Than 500 U.S. Patients to Second Generation Optune within Four Weeks of FDA Approval on July 13
They still showed good improvement on the prescription base though. This company is funding many different trials right now....and earnings releases will dog this company for a while because of that. Until I see indications that
this novel approach to cancer is shy on meeting its endpoints, I'm in.
Analyst's lofty expectations drove this stock price down...not the actual performance of the product. Novel approaches to curing cancer are always met with skepticism, which automatically dictates a slow and steady build.
Analysts never pay attention to this reality.
Having a commercial product that is viable is huge. This keeps this company alive and in play for the foreseeable future.
I agree but the disconnect during quarterly earnings- 50% drops!!!!! This company had $29 IPO intentions and we sit at $7.50
going to be a lot of cash burn that will out pace revenues for at least 3 more years. Still.....it's a prove commercial technology. These would be the best levels to buy it at and check back in 2 years from now.
It won't be earnings releases that will bolster the share price anytime soon, rather an announcement that Medicare is coming on board, which is going to happen, and will be the biggest catalyst for this company.
That could happen in the next 18 months.
Not anymore lol. Terrible company execs-bloated pig
This company sucks and Doyle is awful
One thing I've learned about this company stock is it defies all logic.
Chart is looking great. Really enjoying this play- Quiet before the storm.
Very exciting times!
Looks like your ship may have just came in.
FDA APPROVAL MINUTES AGO. Technical and fundamentals lining up on this one!
Regardless, anywhere in this &10 range is a floor for the stock.
Yup and two weeks from now it will be Bullish. This stock is ridiculous
Great entry point today at 10.64.
This area is a strong floor for this stock.
Commercial stage drug company
With triple digit growth on no Invasive side effects and cash in the bank for next 12 mo this..... Count me in:)
No position currently
You still in this?
Don't fall in love now I'm beginning to hate this bitch
Going back to $30 and beyond $$
Go Go Go
Bet you guys wish you listened to me now $$$$
Everyone vacated here? I see this company going to $50+ in the coming years Jmho
Hmmmm I'm trying to decide if this is a buy right now-
IN at $12 - Looking to breakout - chart screaming buy!
I wouldn't be surprised if nvcr opened $40 plus Monday...real nice news
Novocure's Novel Anti-Cancer Therapy Catches Street Attention FORBES ARTICLE from today
Take a close watchful eye on little known biomedical Novocure (NVCR), whose novel anti-cancer therapy is catching Wall Street’s attention. Its stock has rallied robustly from a low of $15 a share on the day it went public on Oct. 7, 2015, to a high of $30.89 thereafter, before sliding on Nov. 16, to $22. At least one analyst, JMP Securities’ Michael G. King, sees the stock going much higher, rising to at least $43 a share before long.
Novocure went public at an inopportune time – on the day when many investors dumped the biotechnology group because of consumer outrage over the issue of overpriced drugs. As a result, shares of Novocure tumbled some 17% that day. But, no matter. The stock has since rebounded, driven up by the company’s novel product, Optune.
The Food and Drug Administration approved on Oct.5, 2015, Novocure’s lead product, Optune, for the treatment, in combination with temozolomide, of newly diagnosed glioblastoma, the most common type of primary malignant brain tumor. The FDA approval raises the company’s target patient population in the U.S. alone by nearly 70%, according to Novocure analysis.
“Our our sales and marketing team is now actively promoting Optune as a superior therapy for newly diagnosed glioblastoma, as we work to transform the standard of care,” says Asaf Danziger, chief executive officer of Novocure. Optune is the first FDA-approved therapy in more than a decade, he notes, to demonstrate statistically significant extension of survival in newly diagnosed glioblastoma patients.
Novocure points out that some 215 U.S. leading cancer centers have been certified to prescribe Optune as of Sept. 30, 2015, a 10% increase from the prior quarter.
There are nearly 10,000 new cases of primary glioblastoma and their treatment with Optune could help the company generate $1 billion in sales a year within three years, estimates Novocure. Since the company markets the product itself, FDA’s approval alone could mean $700 million-$800 million of profits annually in the U.S., or close to $10 a share, figures some analysts.
With Optune’s approval in the U.S., Europe and Japan, the sales opportunity from glioblastoma alone could be worth more than $2.5 billion, according to JP Morgan analyst Michael G. King. “With no similar therapeutic technologies in existence, or on the horizon, and demonstrated efficacy in combination with the standard of care, we believe tumor treating fields (TTFields), a new treatment modality in oncology, will become part of the new standard of care,” says King, who rates Novocure stock as “outperform.”The FDA approval of Optune “the company faces solid opportunities,” says the analyst.
He believes the company has a “unique business model with its first approved product, representing a hybrid between a device and a therapeutic.”
King, in a recent report to clients, says that the FDA approval of Optune positions the company to penetrate a large market opportunity in glioblastoma. Apart from its effort in seeking approval of Optune, Novocure also has five completed or ongoing phase 2 clinical studies, as well as nine completed pre-clinical studies on various drug candidates.
The FDA approval is being hailed as the most significant advance in brain cancer in more than 10 years and, says King, “should become part of the new reference standard.”
The two-year survival rate among patients treated with Optune in combination with temozolomide was 50% higher than in patients treated with temozolomide alone, according to Novocure’s estimate.
The company continues to work towards expanding its product pipeline. “We remain focused on advancing our clinical pipeline to evaluate the use of Tumor Testing Fields for a variety of additional solid tumors, including ongoing trials in brain metastases, pancreatic cancer, ovarian cancer, and mesotheloma,” says Bill Doyle, Novocure’s executive chairman.
He believes Novocure will “achieve significant growth as we drive adoption of Optune in newly diagnosed glioblastoma and work to transform the standard of care in our first indication.”
Indeed, some big investors believe that with FDA approval of Optune, Novocure has become “the unicorn investment in the treatment of cancer.”
http://www.forbes.com/sites/genemarcial/2015/11/17/novocures-novel-anti-cancer-therapy-catches-street-attention/
Novocure Announces Webcast to Discuss New EF-14 Clinical Trial Analyses and Tumor Treating Fields Presentations from SNO 2015
St. Helier, Jersey – Nov. 17, 2015 – Novocure (NASDAQ: NVCR), a commercial stage oncology company pioneering a novel therapy for solid tumors, announced today that it will hold a webcast on Monday, Nov. 23, 2015, beginning at 4:30 p.m. EST to discuss the new EF-14 analyses and Tumor Treating Fields (TTFields) presentations from the 20th Annual Meeting of the Society of Neuro-Oncology.
The new EF-14 clinical trial analyses to be presented at SNO and that will be discussed during the webcast show the use of TTFields therapy with temozolomide did not adversely affect newly diagnosed GBM patients’ quality of life; and, GBM patients who continued TTFields therapy in combination with chemotherapy, including bevacizumab, at first recurrence lived longer than patients who received chemotherapy alone.
Analysts and investors can participate in the conference call by dialing (877)726-5929 for domestic callers and (530)379-4648 for international callers, using the conference ID 81604390. Access the webcast live from the Investor Relations page of Novocure’s website, where it will be available for replay for 14 days following the call.
http://www.novocure.com/news-and-events/news/2015/11-17-2015.aspx
Novocure Announces 18 Presentations on Tumor Treating Fields at SNO 2015 Including New Analyses of the EF-14 Newly Diagnosed Glioblastoma Clinical Trial Data
Quality of life was maintained throughout treatment with Tumor Treating Fields
EF-14 patients who continued Tumor Treating Fields concurrent with second-line chemotherapy at first recurrence of glioblastoma lived significantly longer than patients who received chemotherapy alone
More >>>>>
http://www.novocure.com/news-and-events/news/2015/11-17-2015-a.aspx
Followers
|
28
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
553
|
Created
|
10/07/15
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |